SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
(Photo: Wikimedia Creative Commons / Pollo)
Doctors: TPP Would Trample Access to Medicines
Médecins Sans Frontières warns that lives hang in balance of secret pact
Jul 08, 2014
International humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF) warned Monday that the highly secretive Trans-Pacific Partnership will further erode access to life saving medicines in all countries involved in the deal, hitting poor and vulnerable people the hardest.
The organization joins a crescendo of voices warning of the potentially deadly effects of the mammoth pact as another round of closed-door negotiations commences in Ottawa, Canada.
"Every TPP government is struggling to contain rising health costs, so it's beyond reason why provisions designed to delay the introduction of low-cost generic medicines would be allowed to make it into the final TPP agreement," said Stephen Cornish, executive director of MSF Canada, in a statement.
The "free trade" deal is currently under negotiation between Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, United States, and Vietnam--which combined comprise approximately 40 percent of the world's GDP.
The U.S. has been aggressively pushing proposals to expand and reinforce pharmaceutical corporations' monopolies on life-saving drugs and restrict the abilities of governments to protect access to lower-cost generic medicines.
The pact is slated to include NAFTA's infamous corporate tribunals, which allow corporations to sue governments in secret courts, circumventing national legal systems. Using this provision in NAFTA, pharmaceutical giant Eli Lilly sued the Canadian government in 2012 on charges that Canada "favors" generic medicines. The secret tribunal ruling has the potential to change Canadian drug laws.
MSF declared in its statement, "To see the harmful effects of the stringent intellectual property rules that the U.S. seeks to impose on TPP countries, we need only look to the U.S. market, where medicine prices have tripled since 1987, outpacing consumer prices, which have only doubled."
"Higher medicine prices cost lives in countries at every level of economic development, and the TPP regulations in question should be rejected outright," said Judit Rius, U.S. manager and legal policy adviser of the MSF Access Campaign.
_____________________
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Sarah Lazare
Sarah Lazare was a staff writer for Common Dreams from 2013-2016. She is currently web editor and reporter for In These Times.
International humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF) warned Monday that the highly secretive Trans-Pacific Partnership will further erode access to life saving medicines in all countries involved in the deal, hitting poor and vulnerable people the hardest.
The organization joins a crescendo of voices warning of the potentially deadly effects of the mammoth pact as another round of closed-door negotiations commences in Ottawa, Canada.
"Every TPP government is struggling to contain rising health costs, so it's beyond reason why provisions designed to delay the introduction of low-cost generic medicines would be allowed to make it into the final TPP agreement," said Stephen Cornish, executive director of MSF Canada, in a statement.
The "free trade" deal is currently under negotiation between Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, United States, and Vietnam--which combined comprise approximately 40 percent of the world's GDP.
The U.S. has been aggressively pushing proposals to expand and reinforce pharmaceutical corporations' monopolies on life-saving drugs and restrict the abilities of governments to protect access to lower-cost generic medicines.
The pact is slated to include NAFTA's infamous corporate tribunals, which allow corporations to sue governments in secret courts, circumventing national legal systems. Using this provision in NAFTA, pharmaceutical giant Eli Lilly sued the Canadian government in 2012 on charges that Canada "favors" generic medicines. The secret tribunal ruling has the potential to change Canadian drug laws.
MSF declared in its statement, "To see the harmful effects of the stringent intellectual property rules that the U.S. seeks to impose on TPP countries, we need only look to the U.S. market, where medicine prices have tripled since 1987, outpacing consumer prices, which have only doubled."
"Higher medicine prices cost lives in countries at every level of economic development, and the TPP regulations in question should be rejected outright," said Judit Rius, U.S. manager and legal policy adviser of the MSF Access Campaign.
_____________________
Sarah Lazare
Sarah Lazare was a staff writer for Common Dreams from 2013-2016. She is currently web editor and reporter for In These Times.
International humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF) warned Monday that the highly secretive Trans-Pacific Partnership will further erode access to life saving medicines in all countries involved in the deal, hitting poor and vulnerable people the hardest.
The organization joins a crescendo of voices warning of the potentially deadly effects of the mammoth pact as another round of closed-door negotiations commences in Ottawa, Canada.
"Every TPP government is struggling to contain rising health costs, so it's beyond reason why provisions designed to delay the introduction of low-cost generic medicines would be allowed to make it into the final TPP agreement," said Stephen Cornish, executive director of MSF Canada, in a statement.
The "free trade" deal is currently under negotiation between Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, United States, and Vietnam--which combined comprise approximately 40 percent of the world's GDP.
The U.S. has been aggressively pushing proposals to expand and reinforce pharmaceutical corporations' monopolies on life-saving drugs and restrict the abilities of governments to protect access to lower-cost generic medicines.
The pact is slated to include NAFTA's infamous corporate tribunals, which allow corporations to sue governments in secret courts, circumventing national legal systems. Using this provision in NAFTA, pharmaceutical giant Eli Lilly sued the Canadian government in 2012 on charges that Canada "favors" generic medicines. The secret tribunal ruling has the potential to change Canadian drug laws.
MSF declared in its statement, "To see the harmful effects of the stringent intellectual property rules that the U.S. seeks to impose on TPP countries, we need only look to the U.S. market, where medicine prices have tripled since 1987, outpacing consumer prices, which have only doubled."
"Higher medicine prices cost lives in countries at every level of economic development, and the TPP regulations in question should be rejected outright," said Judit Rius, U.S. manager and legal policy adviser of the MSF Access Campaign.
_____________________
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.